No results found

Check the spelling or try searching for a more general term.

3rd European Laser Innovations Forum

3rd European Laser Innovations Forum

You are invited to join Ellex in Nice, France, for the 3rd European Laser Innovations Forum. A panel of world-renowned faculty, featuring scientific and clinical insight from John MARSHALL, PhD, FRCPath, FMedSci (Institute of Ophthalmology UCL in association with Moorfields Eye Hospital – London), Andrea CUSUMANO, PhD (Rome Vision Clinic – Rome), Gus GAZZARD, MBBChir, MA, MD, FRCOphth (Moorfields Eye Hospital - London), Paulo E. STANGA, PhD, (London Vision Clinic – London) and Isabelle AKNIN, MD (Clinique Oxford – Cannes). The 3rd European Laser Innovations Forum will address, 2RT™ Retinal Rejuvenation Therapy for eAMD. It will also spotlight recent clinical updates for SLT or Selective Laser Trabeculoplasty.

OVERVIEW

You are invited to join Ellex in Nice, France, for the 3rd European Laser Innovations Forum. A panel of world-renowned faculty, featuring scientific and clinical insight from John MARSHALL, PhD, FRCPath, FMedSci (Institute of Ophthalmology UCL in association with Moorfields Eye Hospital – London), Andrea CUSUMANO, PhD (Rome Vision Clinic – Rome), Gus GAZZARD, MBBChir, MA, MD, FRCOphth (Moorfields Eye Hospital - London), Paulo E. STANGA, PhD, (London Vision Clinic – London) and Isabelle AKNIN, MD (Clinique Oxford – Cannes). The 3rd European Laser Innovations Forum will address, 2RT™ Retinal Rejuvenation Therapy for eAMD. It will also spotlight recent clinical updates for SLT or Selective Laser Trabeculoplasty.

AGENDA

WELCOME COCKTAIL RECEPTION
Welcome Cocktail Reception in Le Negresco from 8:00pm on Friday, 6th March 2020


LFT - LASER VITREOLYSIS
Moderators: Prof. Paulo Stanga, Dr. Isabelle Aknin• Clinical Experience and Case Reports: The Vision of the Vitreo-Retinal Surgeon

• How to Start with Laser Vitreolysis and Avoiding Pitfalls
• Floaters Management: Monitoring, Laser Vitreolysis or Vitrectomy?


SLT SELECTIVE LASER TRABECULOPLASTY
Moderators: Prof. John Marshall, Prof. Gus Gazzard

• Redo Time for Selective Laser Trabeculoplasty
• Over 1500 Treatments, Considering SLT as Primary Therapy
• SLT versus Eye Drops for First-Line Treatment


2RT™ - RETINAL REJUVENATION THERAPY
Moderators: Prof. John Marshall, Prof. Andrea Cusumano

• From SLT to 2RT™: The Mechanism of Action of Nanopulse Laser
• Early AMD Pathogenesis, Early Stages of Progression
• Clinical Experience and Case Reports with 2RT™ for AMD and CSME
• 2RT™ Retinal Rejuvenation: A Must for Maculopathy• Retinal Function Following Nanosecond 2RT™ Laser Treatment for Intermediate AMD: Changes in Treated and Fellow Eyes
• 2RT™: 4th Year Post LEAD Review

HDCap™ CAPSULOTOMY
Moderators: Prof. Paulo Stanga, Dr. Isabelle Aknin

• HDCap™ Capsulotomy: the new paradigm in managing PCO
• Identifying and treatment capsular fragments


3rd European Laser Innovations Forum

Date: Saturday, 7th March, 2020
Time: 9.00 am – 4.30 pm
Venue: Hotel Le Negresco
37, Promenade des Anglais
06000 Nice, France

Note: Welcome Cocktail Reception will be held in Le Negresco from 8:00pm on Friday, 6th March 2020.

Due to the limited number of places available, registration confirmation is required on or before 29 March 2019.

REGISTRATION FEE:
Early-bird rate: 90.00 EUR (January 31 2020 deadline)
Full rate: 120.00 EUR

RECOMMENDED ACCOMMODATION:
Hôtel WEST END Nice
31, Promenade des Anglais, 06000 Nice – France

To book your accommodation with special rates contact: fchecinski@ellex.com by 31 January 2020.

FACULTY

Isabelle Aknin
MD (France)
John Marshall
PhD, FMedSci, FRCPath, FRCOphth (Hon) (UK)
Paulo E. Stanga
MD, PhD (UK)
Andrea Cusumano
MD, PhD (Italy)
Gus Gazzard
MBBChir, MA, MD, FRCOphth (UK)

FACULTY

About John Marshall, PhD, FRCPath, FMedSci

Professor John Marshall is an Emeritus Professor of Ophthalmology at Kings College London, and Honorary Distinguished Professor University of Cardiff. His research over the past forty years has ranged over a number of ocular problems but has concentrated on the interrelationships between light and ageing, the environmental mechanisms underlying age-related, diabetic and inherited retinal disease, and the development of lasers for use in ophthalmic diagnosis and surgery. This work has resulted in over four hundred research papers and 41 book chapters and 7 books. He has held posts chairing the medical advisory boards of many international companies and was a director of Diomed for some years, this being the leading supplier of diode laser systems for surgery. He is a Fellow of several national ophthalmological societies, as well as being elected to the European Academy of Ophthalmology.

About Andrea Cusumano, PhD

By carrying out scientific work in parallel at three different faculties and schools of ophthalmology, Dr. Cusumano has been able to apply the most advanced clinical and surgical research from all over the world.

Dr. Cusumano’s primary focus is applying innovative ophthalmalogical techniques – using laser technology, ultrasound, new biomaterials and intraocular endoscopic techniques. He has taken part in the development of numerous clinical, diagnostic, and surgical innovations, which have advanced the field of ophthalmology as a whole.

About Gus Gazzard, MBBChir, MA, MD, FRCOphth (Moorfields Eye Hospital - London)

Based in Moorfields London (one of the world’s leading eye hospitals) as well as other private clinics in London, Gus has considerable experience in his chosen field, developed through decades of work and research both within the UK and internationally.

His primary areas of expertise are Cataracts, Glaucoma and the medical, laser and surgical treatment of glaucoma, including small incision and complex cataract surgery. Professor Gazzard is the recipient of the prestigious, competitively awarded “NHS National Silver Merit Award” and is both organiser and lecturer at The Moorfields International Glaucoma Symposium (MIGS).

Gus’s research has included clinical trials of Glaucoma surgery and currently he is the Chief Investigator of the LiGHT Trial of Laser Treatment for Glaucoma, a major study into the most effective use of selective laser trabeculoplasty (SLT).

About Paulo E. Stanga, MD, PhD

Prof. Paulo E. Stanga is a former Consultant Ophthalmologist and Vitreoretinal Surgeon for the Manchester Royal Eye Hospital, Professor of Ophthalmology and Retinal Regeneration for the University of Manchester and Director of the Manchester Vision Regeneration (MVR) Lab at NIHR/Wellcome Trust Manchester CRF.

Prof. Stanga specialises in vitreo-retinal disorders that require either medical or surgical treatment. Since 1993, Prof. Stanga has worked in the development and application of new outpatient and surgical therapies and technologies such as retrobulbar Interferon alpha-2a, genetics of AMD, retinal pigment epithelium translocation surgery, macular translocation surgery, micropulse diode and Pascal® laser photocoagulation, Time and Spectral Domain and Swept-Source (DRI-OCT1 Atlantis®) optical coherence tomography (OCT), wide-angle (Optos®) fundus fluorescein angiography and fundus autofluorescence technology, antiangiogenic intravitreal drugs and high speed phaco/vitrectomy surgical systems.

His current research interests are in the pharmacological, surgical and laser treatment of proliferative diabetic retinopathy and macular oedema, laser-tissue interaction, electronic retinal implants for artificial vision, non-cutter based high-speed vitrectomy, gene therapy and robotic surgery.

About Isabelle Aknin, MD

Ophthalmological practice in Golfe-Juan, specializing in retinal pathologies and pathologies of ocular aging.
Retinal exploration Center at the Private Hospital Oxford in Cannes.
Aesthetic consultations at the Private Hospital Oxford in Cannes.
Member of SFO, American Diabetes Association, ARVO, American Academy of Ophthalmology, International Ocular Inflammation Society and Usher Syndrome Coalition.
Board of the French Retinal Society.
Former lecturer at the Faculty of Pharmacy, University of Dijon.
2009 Prize of the French Retinal Society.
President of ARMD: Association de la Rétine MeDiterranéenne.

ABOUT ELLEX

SLT FROM ELLEX

Ellex’s proprietary SLT technology delivers superior energy control, a sharp-edged aiming beam and the industry’s fastest firing rate of three shots per second. It's a capability that's being used every day by thousands of physicians around the world to visualize the trabecular meshwork in greater detail, and to perform procedures faster and with improved accuracy, delivering better patient outcomes - reliably, accurately and safely.

FLOATER MANAGEMENT FROM ELLEX

Ellex was the first company to pioneer a laser designed specifically for the treatment of floaters. Our Reflex Technology™ platform features True Coaxial Illumination™ (TCI), on and off-axis modes, a precise aiming beam and a superior energy beam profile. It’s an approach that maximizes focusing accuracy and provides a safe and highly effective tool for the treatment of vitreous opacities.

REFLEX TECHNOLOGY FROM ELLEX

With Ellex’s proprietary Reflex Technology™ visualizing floaters and opacities, and assessing their position relative to the lens or retina, has never been easier.

“Featuring coaxial (on) and off-axis illumination, Reflex Technology allows for clear visualization of the internal eye from the cornea all the way to the retina, and as such, provides much-needed spatial context for procedures like laser floater treatment.”

Paul I. Singh, MD
The Eye Centers of Racine and Kenosha, USA

2RT™ RETINAL REJUVENATION FROM ELLEX

Retinal Rejuvenation Therapy, 2RT, stimulates a biological healing process that results in cellular rejuvenation, renewing the entire transport mechanism of the retina and improving the hydraulic conductivity of Bruch’s membrane. This rejuvenation process preserves or improves functional vision and reduces disease progression — without causing collateral damage to the overlying photoreceptor rods and cones of the retina. 2RT™ offers the potential to intervene earlier in the treatment of AMD before significant vision loss has occurred to slow the degeneration process.

“The major difference between 2RT™ nanopulse laser therapy and conventional lasers is the difference in the responses in the patient. With a conventional laser, you will always get some collateral damage to the light sensitive cells. With 2RT™ being this disruptive mechanism, we have no collateral damage and therefore we get the therapeutic effect with none of the collateral effects of damage to the light sensitive cells.”

Prof. John Marshall
Emeritus Professor of Ophthalmology, King’s College London
Honorary distinguished Professor in Visual Science, University of Cardiff

Ellex is the manufacturer of 2RT™. It has been approved for the indications Clinically Significant Macular Edema (CSME) and in patients with early Age-Related Macular Degeneration (AMD) where it can produce bilateral improvements in macular appearance and function under CE marking. Ellex does not accept any responsibility for use of the system outside of these indications. The material presented herein may include the views or recommendations of third parties and does not necessarily reflect the views of Ellex Medical Pty Ltd.

2RT™ has a CE Mark (Conformité Européenne) for treatment in patients with early AMD where it can produce bilateral improvements in macular appearance and function.

2RT™ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) (510k) Market release for the treatment of Clinically Significant Macula Edema (CSME).

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More